[{"address1": "910 Clopper Road", "address2": "Suite 201S", "city": "Gaithersburg", "state": "MD", "zip": "20878", "country": "United States", "phone": "240 654 1450", "website": "https://altimmune.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.", "fullTimeEmployees": 59, "companyOfficers": [{"maxAge": 1, "name": "Dr. Vipin K. Garg Ph.D.", "age": 65, "title": "President, CEO & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 986142, "exercisedValue": 0, "unexercisedValue": 4219457}, {"maxAge": 1, "name": "Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS", "age": 70, "title": "Chief Medical Officer", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 681809, "exercisedValue": 0, "unexercisedValue": 1413049}, {"maxAge": 1, "name": "Mr. Raymond M. Jordt M.B.A.", "age": 50, "title": "Chief Business Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 578850, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gregory L. Weaver CPA, M.B.A.", "age": 67, "title": "Chief Financial Officer", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Shutterly M.S.", "age": 35, "title": "Principal Financial & Accounting Officer and Corporate Controller", "yearBorn": 1988, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bertrand  Georges Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. M. Scot Roberts Ph.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 599255, "exercisedValue": 0, "unexercisedValue": 565469}, {"maxAge": 1, "name": "Mr. Tony  Blandin B.S.", "title": "Vice President of Quality & Compliance Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 4, "compensationRisk": 10, "shareHolderRightsRisk": 4, "overallRisk": 7, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://ir.pharmathene.com/phoenix.zhtml?c=191999&p=irol-irhome", "maxAge": 86400, "priceHint": 2, "previousClose": 8.18, "open": 8.3, "dayLow": 8.18, "dayHigh": 8.75, "regularMarketPreviousClose": 8.18, "regularMarketOpen": 8.3, "regularMarketDayLow": 8.18, "regularMarketDayHigh": 8.75, "exDividendDate": 1484870400, "beta": 0.072, "forwardPE": -7.5457544, "volume": 4883979, "regularMarketVolume": 4883979, "averageVolume": 3074637, "averageVolume10days": 3230480, "averageDailyVolume10Day": 3230480, "bid": 6.26, "ask": 10.53, "bidSize": 200, "askSize": 200, "marketCap": 586777920, "fiftyTwoWeekLow": 5.275, "fiftyTwoWeekHigh": 14.84, "priceToSalesTrailing12Months": 11284.19, "fiftyDayAverage": 7.8803, "twoHundredDayAverage": 7.427025, "currency": "USD", "enterpriseValue": 449171168, "floatShares": 70596880, "sharesOutstanding": 71124600, "sharesShort": 23434782, "sharesShortPriorMonth": 22936698, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.32950002, "heldPercentInsiders": 0.00794, "heldPercentInstitutions": 0.56678003, "shortRatio": 5.81, "shortPercentOfFloat": 0.33040002, "impliedSharesOutstanding": 71124600, "bookValue": 1.875, "priceToBook": 4.4, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -103520000, "trailingEps": -1.57, "forwardEps": -1.47, "lastSplitFactor": "1:30", "lastSplitDate": 1536883200, "enterpriseToRevenue": 8637.907, "enterpriseToEbitda": -4.528, "52WeekChange": -0.24794894, "SandP52WeekChange": 0.2421279, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ALT", "underlyingSymbol": "ALT", "shortName": "Altimmune, Inc.", "longName": "Altimmune, Inc.", "firstTradeDateEpochUtc": 1495805400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "dfbfc9cc-7a23-3560-b04c-b1a5faf1ec3e", "messageBoardId": "finmb_4866807", "gmtOffSetMilliseconds": -18000000, "currentPrice": 8.25, "targetHighPrice": 28.0, "targetLowPrice": 12.0, "targetMeanPrice": 22.85714, "targetMedianPrice": 25.0, "recommendationMean": 1.625, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 139380000, "totalCashPerShare": 1.96, "ebitda": -99191000, "totalDebt": 1773000, "quickRatio": 16.522, "currentRatio": 16.874, "totalRevenue": 52000, "debtToEquity": 1.329, "revenuePerShare": 0.001, "returnOnAssets": -0.39558998, "returnOnEquity": -0.72959, "freeCashflow": -45628000, "operatingCashflow": -78116000, "revenueGrowth": -0.986, "operatingMargins": -4953.4, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-21"}]